SIETES :: 93213 citas

Resultados de la búsqueda por GOTA REFINAR BÚSQUEDA

1.

Herman AO. FDA approves new cholesterol-lowering drug. Journal Watch 2020:24 de febrero. [Ref.ID 103538]

2.

Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2020:1. [Ref.ID 103506]

3.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

4.

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, for the CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:29 de marzo. [Ref.ID 102489]

5.

Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;388:2039-52. [Ref.ID 100912]

6.

Anónimo. EMA releases clinical trial data in transparency effort. DIA Daily 2016:1. [Ref.ID 100849]

7.

Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-007. [Ref.ID 100745]

8.

Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-7. [Ref.ID 100660]

9.

Solomon DH, Liu C-C, Kuo I-H, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims . Ann Rheum Dis 2016;75:1674-9. [Ref.ID 100659]

10.

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

11.

Anónimo. Fébuxostat et syndrome de lyse tumorale. Prescrire 2016;36:177-8. [Ref.ID 100526]

12.

Rainer TH, Cheng CH, Janssens HJEM, Man CY, Tam S, Choi YF, Yau WH, Lee KH, Graham CA. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016;164:464-71. [Ref.ID 100200]

13.

Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 2015:18 de noviembre. [Ref.ID 99808]

14.

Anónimo. EMA approves two lung cancer drugs. DIA Daily 2015:21 de diciembre. [Ref.ID 99745]

15.

Yang C-Y, Chen CH, Deng S-T, Huang C-S, Lin Y-J, Chen Y-J, Wu C-Y, Hung S-L, Chung W-H. Allopurinol use and risk of fatal hypersensitivity reactions: A nationwide population-based study in Taiwan. JAMA Intern Med 2015;175:1550-7. [Ref.ID 99256]

16.

Anónimo. Diphosphonates: pseudo-gouttes. Prescrire 2014;34:833. [Ref.ID 98466]

17.

Anónimo. Colchicine: encore des morts. Prescrire 2014;34:266. [Ref.ID 97438]

18.

Anónimo. Drugs for gout. Med Lett Drugs Ther 2014;56:22-4. [Ref.ID 97423]

19.

Anónimo. Pégloticase (Krystexxa). Un hypo-uricémiant trop dangereux et trop peu évalué. Prescrire 2014;34:174-8. [Ref.ID 97360]

20.

Anónimo. Canakinumab (Ilaris) et traitement des crises de goutte. Prescrire 2014;34:173-4. [Ref.ID 97359]